Provided By GlobeNewswire
Last update: Sep 5, 2023
MONT-SAINT-GUIBERT, Belgium, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on 04 September 2023, of 3,930,770 new shares of Celyad Oncology SA (the “Company”) to Tolefi and an affiliate of Fortress Investment Group as well as other historical shareholders. As a result, the Company’s share capital has been increased to 80,628,224.49 EUR and is represented by 26,524,726 shares.